Aya Jakobovits - 05 Jun 2024 Form 4 Insider Report for Adicet Bio, Inc. (ACET)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
07 Jun 2024, 16:06:37 UTC
Prior SEC filing
16 Aug 2023
Next SEC filing
23 Aug 2024
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Nick Harvey, Attorney-in-Fact

Key filing fact

Aya Jakobovits filed Form 4 for Adicet Bio, Inc. (ACET) on 07 Jun 2024.

Key facts

  • This page summarizes Aya Jakobovits's Form 4 filing for Adicet Bio, Inc. (ACET).
  • 2 reported transactions and 1 derivative row are listed below.
  • Accepted by SEC: 07 Jun 2024, 16:06.

Change

  • Previous filing in this sequence was filed on 16 Aug 2023.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ACET transaction

Common Stock

Award

Transaction value
$0
Shares
+5,900
Change %
+100%
Price
$0.000000
Shares after
11,800
Date
05 Jun 2024
Ownership
Direct
Footnotes
F1
ACET holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
356,343
Date
05 Jun 2024
Ownership
See Footnote
Footnotes
F2
ACET holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
356,343
Date
05 Jun 2024
Ownership
See Footnote
Footnotes
F3
ACET holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
138,076
Date
05 Jun 2024
Ownership
See Footnote
Footnotes
F4

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ACET transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
$0
Shares
+26,400
Change %
Price
$0.000000
Shares after
26,400
Date
05 Jun 2024
Ownership
Direct
Underlying class
Common Stock
Underlying amount
26,400
Exercise price
$1.44
Footnotes
F5
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

The Reporting Person was issued Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs shall vest in full on the earlier to occur of (i) the first anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors. The RSUs may be settled only by delivering shares of Common Stock, and thus, the grant is being reported in Table I as allowed per SEC guidance.

Footnote F2

Shares held in a trust of which Dr. Jakobovits' spouse is the trustee and Dr. Jakobovits' daughter is the beneficiary.

Footnote F3

Shares held in a trust of which Dr. Jakobovits' spouse is the trustee and Dr. Jakobovits' son is the beneficiary.

Footnote F4

Shares held in a revocable trust of which Dr. Jakobovits and her spouse are co-trustees.

Footnote F5

These shares shall vest in full on the earlier to occur of (i) the first anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .